Haupenthal, J., Bihrer, V., Korkusuz, H., Kollmar, O., Schmithals, C., et al. (2012) Reduced Efficacy of the PLK1 Inhibitor Bi 2536 on the Progression of Hepatocellular Carcinoma Due to Low Intratumoral Drug Levels. Neoplasia (New York, N.Y.), 14, 410-419.
https://doi.org/10.1596/neo.111366

has been cited by the following article:

• TITLE: PLK1 Is Implicated in the Poor Prognosis of Hepatocellular Carcinoma

  AUTHORS: Ruifeng Xun, Hougen Lu, Xianwang Wang

  KEYWORDS: PLK1, HCC, TCGA, Biomarker, Cancer Therapy

  JOURNAL NAME: Yangtze Medicine, Vol.4 No.3, June 30, 2020

  ABSTRACT: We aimed to identify if PLK1 could be used as a new diagnostic and therapeutic biomarker in hepatocellular carcinoma (HCC) patient. Expression of PLK1 in HCC was analyzed by using GEPIA (Gene Expression Profiling Interactive Analysis) and UALCAN databases. GEPIA and CBioPortal tools were applied to determine patients’ survival and PLK1 mutations, respectively. PPI (Protein-Protein Interaction) networks were further built by STRING (Search Tool for the Retrieval of Interacting Genes) and Metascape Web portals. The data demonstrated that the expression of PLK1 in HCC was significantly enhanced when compared to normal liver tissues (P